Reach Us +1-217-403-9671
Editor - Teresinha Leal | Université catholique de Louvain Brus | 18979
ISSN: 2472-1018

Journal of Lung Diseases & Treatment
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Teresinha Leal

Teresinha Leal
Teresinha Leal
Louvain Centre for Toxicology and Applied Pharmacology (LTAP)
Institute of Experimental and Clinical Research (IREC)
Université catholique de Louvain Brussels


Half-time Clinical and Basic Researcher, IREC/UCL, Brussels-Belgium
Half-time Clinical and Basic Researcher, FRSM, Brussels-Belgium
Permanent Part-time Associate Professor, Université catholique de Louvain, Brussels-Belgium

Research Interest

My major research interest in the clinical field is to contribute to the biochemical diagnosis of the autosomal genetic disease Cystic Fibrosis (CF). I am in charge of the supervision of the sweat test at St Luc University Hospital (~300 tests/year). Have been involved in the development and standardization of the nasal potential difference test for which I have acquired a great internationally recognized expertise.

• In the experimental field, I have developed (since 2004) a research unit in my department. Several projects are studied using a CF mouse model colony homozygous for the most common CF mutation, the F508del mutation. Briefly, the main projects consist on investigating: the underlying mechanisms of lung inflammation in CF and its modulation by azithromycin and other anti-inflammatory drugs; the pathophysiological mechanisms of CF regarding the respiratory and the gastrointestinal tract; the role of small drug molecules (selective phosphodiesterase type 5 inhibitors, resveratrol, ….) as activators of the mutant CFTR protein in CF and potential therapies for CF disease.



Global Speakers in the subject

Global Experts in the subject

Leave Your Message 24x7